Medanta's newest flagship generated Rs90.6 crore of revenue in its first financial year and lost almost as much at the operating level. The 550-bed Noida hospital reported an EBITDA loss of Rs78.3 crore in FY26 as Global Health hired specialists, opened theatres and installed complex-care programmes ahead of mature demand. For Naresh Trehan, Medanta's founder, chairman and managing director, that loss is the cost of building a clinical institution. For shareholders, it is also a deadline.
The ramp-up is moving in the right direction. Noida's quarterly EBITDA loss fell to Rs23.6 crore in the March period from a peak of Rs32 crore in the preceding quarter, even as operational beds increased to 382. The facility had 98 intensive-care beds, 14 operating theatres, more than 200 doctors and over 75 senior clinicians by year-end. It performed more than 1,600 surgeries and 5,000 catheter-laboratory procedures and introduced kidney transplant, bone-marrow transplant and CAR-T programmes.
Those are substantial clinical milestones for a new hospital. They do not yet answer the capital question. Medanta's consolidated FY26 revenue rose 19.4 per cent to Rs4,410.3 crore, while EBITDA grew only 10.4 per cent to Rs1,056 crore and the margin fell to 23.4 per cent. Excluding Noida, EBITDA increased about 19 per cent and the margin improved to 25.7 per cent. The difference shows both the strength of the mature network and the burden of building the next one.
Noida is a network bet, not a single building
The strategic case begins with location. Noida and western Uttar Pradesh contain a large, increasingly insured population with rising demand for tertiary and quaternary care. The hospital is connected to Delhi's wider medical market but can serve patients who might otherwise travel to Gurugram or central Delhi. Its breadth across cardiology, oncology, neurosciences, gastroenterology, orthopaedics and transplant gives Medanta multiple routes to build referrals.
Trehan's model has always centred on high-acuity, multidisciplinary medicine rather than a collection of lightly integrated specialties. That approach can generate strong revenue per occupied bed because difficult cases use several departments, diagnostics and critical care. It also raises fixed costs. Senior clinicians, transplant infrastructure, robotic systems and intensive-care staffing must be available before utilisation is high. The economic payoff arrives only when reputation and referral density fill that capacity.
Noida secured national hospital accreditation within six months and obtained important insurer, corporate, public-sector and central-government empanelments. These steps widen the patient funnel and reduce the risk that capacity sits idle. They also change the payer mix. Government schemes and institutional contracts can deliver volume at lower tariffs and with slower collections than self-pay patients. Management must balance utilisation with cash realisation rather than chase occupancy at any price.
The hospital's proximity to Medanta Gurugram creates both synergy and cannibalisation risk. Shared protocols, brand and specialist networks can accelerate Noida's ramp. Yet some patients may shift from one Medanta facility to another rather than represent new group demand. The relevant measure is incremental network revenue and return, not Noida's stand-alone growth. A new flagship creates value when it expands reach and improves referral allocation across the system.
Mature hospitals are funding the future
Medanta's established portfolio remains highly profitable. Mature hospitals generated FY26 revenue of Rs2,848.2 crore, up 9 per cent, and EBITDA of Rs694.6 crore, up 7.2 per cent. Developing hospitals excluding Noida produced Rs1,413 crore of revenue and Rs444.7 crore of EBITDA, a 31.5 per cent margin. Lucknow, Patna and Ranchi show that newer facilities can become strong earnings contributors after clinical programmes and local referrals develop.
That history supports patience with Noida, but each market has different dynamics. Lucknow established Medanta in a state capital with substantial unmet demand. Noida sits in a more competitive metropolitan region, where Apollo, Fortis, Max and other providers already attract specialists and insured patients. Hiring a distinguished doctor can bring a referral base, but clinician guarantees and revenue-sharing arrangements may defer margin improvement.
Group volume growth was strong in FY26: inpatient count rose 16 per cent and outpatient encounters increased 18.7 per cent. Average revenue per occupied bed advanced 6.1 per cent to Rs66,550, supported by case mix and a shorter average stay of 3.04 days. Occupancy was about 62 per cent on the expanded capacity, or 64 per cent excluding Noida. These figures leave room for growth without proportionate new capital.
The best near-term return may therefore come from filling current beds and adding capacity around successful clusters. Brownfield growth uses existing brands, clinicians and support functions. Greenfield projects require all of those foundations to be built. Trehan's challenge is to prevent the excitement of a national footprint from outrunning the utilisation opportunity already on Medanta's balance sheet.
The project pipeline raises the stakes
Medanta added 623 beds in FY26, a 20.5 per cent increase, including Noida, 131 beds at Patna and a new 110-bed Ranchi hospital. It has also committed to a 400-bed facility in Varanasi through a build-to-suit lease structure, acquired land for a hospital of more than 400 beds in Guwahati and bought an approximately 80-bed facility near its existing Indore hospital to add oncology capability.
The structures show some capital discipline. At Varanasi, the partner will fund the shell while Medanta invests in mechanical systems, interiors and medical equipment. The nearby Indore acquisition can share referrals and infrastructure with an existing hospital. Guwahati, by contrast, requires a new institution in a market with different clinician supply and patient flows. Each project should have its own occupancy, cash and return milestones rather than sit inside a single expansion narrative.
Lease-based growth lowers upfront property expenditure but creates fixed obligations. Accounting may place some costs below EBITDA, making a leased hospital appear more capital-light than its economic commitments suggest. Investors should examine post-lease cash flow and return on total invested capital. A build-to-suit arrangement transfers construction funding, not demand risk.
Consolidated return on capital employed declined to 14.9 per cent in FY26 from 18.1 per cent as Noida and other projects absorbed investment. Excluding Noida and projects, the figure was 23.4 per cent. That gap is the forward investment case in one line. If new hospitals mature well, consolidated return should converge upward. If successive projects enter ramp-up before predecessors stabilise, the gap can persist even while revenue rises.
Clinical leadership must become organisational
Trehan's reputation as a cardiac surgeon gave Medanta an unusually clear clinical identity. The Gurugram flagship was designed around institutes that collaborate on complex patients, and the brand still benefits from founder-led medical authority. At this stage of expansion, the model has to operate without Trehan personally arbitrating every clinical standard or recruitment decision.
Global Health has a professional group chief executive and hospital leadership teams, which is essential. The next institutional step is to make quality, outcomes and physician governance consistent across Noida, Lucknow, Patna, Ranchi, Indore and future sites. A national network cannot rely solely on input measures such as beds, doctors and equipment. It needs comparable data on infections, readmissions, mortality, patient experience and appropriateness of care.
That discipline also protects the brand during rapid hiring. Medanta onboarded more than 550 doctors during FY26, including more than 200 senior clinicians. Growth at that pace can dilute culture if incentives emphasise revenue over multidisciplinary judgement. Trehan's legacy will be more durable if clinical authority sits in peer-led systems that can challenge commercial pressure.
Succession deserves equal attention. Trehan is both chairman and managing director, while expansion commitments stretch years beyond the opening of a facility. Investors need confidence that capital allocation and clinical standards will survive leadership transition. A clear separation of board oversight, executive management and medical governance would reduce key-person risk without weakening the founder's influence.
Asian demand does not remove affordability pressure
Medanta's international-patient revenue grew 33 per cent to Rs278 crore in FY26, increasing its share of group revenue to 7 per cent. Patients from Africa, Southeast Asia, the Commonwealth of Independent States and the Middle East support complex-care volumes. Noida's proximity to Delhi's airport should widen that funnel as the hospital gains recognition.
Medical travel is useful but volatile. Flight disruptions affected fourth-quarter international revenue, and geopolitical tension can change flows quickly. Exchange rates and visa policy also matter. New hospitals should be viable on domestic demand, with international patients improving case mix rather than covering fixed costs. India's own burden of cancer, heart disease and neurological conditions provides ample demand if care remains accessible.
Affordability will become more visible as Medanta enters Varanasi and Guwahati. Advanced care outside metros is a compelling social and commercial proposition, but household purchasing power and public tariffs differ. The group must adapt room mix, packages and referral partnerships without compromising clinical capability. A premium brand can command trust; it cannot assume metropolitan pricing in every city.
Noida is now the most informative test of Trehan's expansion system. By the end of FY27, the hospital should show sustained occupancy growth, a clear path to positive EBITDA and evidence that referrals are incremental to Gurugram. Group return on capital should begin recovering even as the next projects advance. If Noida converts clinical scale into cash on schedule, Medanta will have a repeatable blueprint for northern and eastern India. If losses linger, the 550-bed flagship will warn that the next thousand beds are arriving too soon.
